dendreon stirs on fda news investors piled into dendreon corp options as the biopharmaceutical company seeks regulatory approval for its prostate cancer drug the seattle drug company said its prostate cancer drug candidate provenge was awarded priority review status by the food and drug administration it expects the fda decision by may dendreon shares rose to &# priority review usually takes six months compared with the regular month review time as such traders were taking positions by purchasing may put and call options both the may puts and calls saw activity which randy frederick director of derivatives at charles schwab said was likely a long straddle strategy the strategy entails buying calls and puts at the same strike price and expiration date with the hope that the stock will make a drastic move in addition may puts which give contract holders the right to sell the stock at &# in may saw more activity than usual with more than contracts changing hands compared with open interest of 
